Small molecule targeting of protein-protein interactions through allosteric modulation of dynamics

Molecules

Volumn 20, Issue 9, 2015, Pages 16435-16445

  Cossins, Benjamin P ^a   Lawson, Alastair D G ^a  

^a UCB ^*  (United Kingdom)

Author keywords

Allosteric; Protein dynamics; Protein protein interaction; Small molecule

Indexed keywords

MOLECULAR LIBRARY; PROTEIN; PROTEIN BINDING;

ALLOSTERISM; BINDING SITE; CHEMISTRY; MOLECULAR LIBRARY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; PROTEIN BINDING; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84942693284     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200916435     Document Type: Review

References (78)

1. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727-730.
2. Overington, J.P.; Al-Lazikani, B.; Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov. 2006, 5, 993-996.
3. Teague, S.J. Learning lessons from drugs that have recently entered the market. Drug Discov. Today 2011, 16, 398-411.
4. Arkin, M.R.; Tang, Y.; Wells, J.A. Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality. Chem. Biol. 2014, 21, 1102-1114.
5. Jubb, H.; Higueruelo, A.P.; Winter, A.; Blundell, T.L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol. Sci. 2012, 33, 241-248.
6. Makley, L.N.; Gestwicki, J.E. Expanding the Number of "Druggable" Targets: Non-Enzymes and Protein-Protein Interactions. Chem. Biol. Drug Des. 2013, 81, 22-32.
7. Bunnage, M.E. Getting pharmaceutical R & D back on target. Nat. Chem. Biol. 2011, 7, 335-339.
8. Venkatesan, K.; Rual, J.-F.; Vazquez, A.; Stelzl, U.; Lemmens, I.; Hirozane-Kishikawa, T.; Hao, T.; Zenkner, M.; Xin, X.; Goh, K.-I.; et al. An empirical framework for binary interactome mapping. Nat. Methods 2009, 6, 83-90.
9. Basse, M.J.; Betzi, S.; Bourgeas, R.; Bouzidi, S.; Chetrit, B.; Hamon, V.; Morelli, X.; Roche, P. 2P2Idb: A structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 2013, 41, D824-D827.
10. Labbé, C.M.; Laconde, G.; Kuenemann, M.A.; Villoutreix, B.O.; Sperandio, O. iPPI-DB: A manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov. Today 2013, 18, 958-968.
11. Higueruelo, A.P.; Jubb, H.; Blundell, T.L. TIMBAL v2: Update of a database holding small molecules modulating protein-protein interactions. Database 2013, 2013, doi:10.1093/database/bat039.
12. Reynès, C.; Host, H.; Camproux, A.-C.; Laconde, G.; Leroux, F.; Mazars, A.; Deprez, B.; Fahraeus, R.; Villoutreix, B.O.; Sperandio, O. Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods. PLoS Comput. Biol. 2010, 6, e1000695.
13. Yin, H.; Hamilton, A.D. Strategies for Targeting Protein-Protein Interactions with Synthetic Agents. Angew. Chem. Int. Ed. 2005, 44, 4130-4163.
14. Gavenonis, J.; Sheneman, B.A.; Siegert, T.R.; Eshelman, M.R.; Kritzer, J.A. Comprehensive analysis of loops at protein-protein interfaces for macrocycle design. Nat. Chem. Biol. 2014, 10, 716-722.
15. Chang, Y.S.; Graves, B.; Guerlavais, V.; Tovar, C.; Packman, K.; To, K.-H.; Olson, K.A.; Kesavan, K.; Gangurde, P.; Mukherjee, A.; et al. Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. USA 2013, 110, E3445-E3454.
16. Whitty, A.; Zhou, L. Horses for courses: Reaching outside drug-like chemical space for inhibitors of challenging drug targets. Future Med. Chem. 2015, 7, 1093-1095.
17. Wilson, A.J. Helix mimetics: Recent developments. Prog. Biophys. Mol. Biol. 2015, in press.
18. Block, P.; Weskamp, N.; Wolf, A.; Klebe, G. Strategies to search and design stabilizers of protein-protein interactions: A feasibility study. Proteins Struct. Funct. Bioinform. 2007, 68, 170-186.
19. Sadowsky, J.D.; Burlingame, M.A.; Wolan, D.W.; McClendon, C.L.; Jacobson, M.P.; Wells, J.A. Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl. Acad. Sci. USA 2011, 108, 6056-6061.
20. Van Westen, G.J.P.; Gaulton, A.; Overington, J.P. Chemical, Target, and Bioactive Properties of Allosteric Modulation. PLoS Comput. Biol. 2014, 10, e1003559.
21. Van Westen, G.J.P. Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333CC Leiden, The Netherlands. Personal Communication, 2015.
22. Del Sol, A.; Tsai, C.-J.; Ma, B.; Nussinov, R. The origin of allosteric functional modulation: Multiple pre-existing pathways. Structure 2009, 17, 1042-1050.
23. Motlagh, H.N.; Wrabl, J.O.; Li, J.; Hilser, V.J. The ensemble nature of allostery. Nature 2014, 508, 331-339.
24. Itoh, K.; Sasai, M. Entropic mechanism of large fluctuation in allosteric transition. Proc. Natl. Acad. Sci. USA 2010, 107, 7775-7780.
25. Ma, B.; Tsai, C.-J.; Haliloʇlu, T.; Nussinov, R. Dynamic Allostery: Linkers Are Not Merely Flexible. Structure 2011, 19, 907-917.
26. Zhuravlev, P.I.; Papoian, G.A. Protein functional landscapes, dynamics, allostery: A tortuous path towards a universal theoretical framework. Q. Rev. Biophys. 2010, 43, 295-332.
27. Tsai, C.-J.; Nussinov, R. A Unified View of "How Allostery Works." PLoS Comput. Biol. 2014, 10, e1003394.
28. Tsai, C.-J.; del Sol, A.; Nussinov, R. Allostery: Absence of a change in shape does not imply that allostery is not at play. J. Mol. Biol. 2008, 378, 1-11.
29. Fenley, A.T.; Muddana, H.S.; Gilson, M.K. Entropy-Enthalpy transduction caused by conformational shifts can obscure the forces driving protein-ligand binding. Proc. Natl. Acad. Sci. USA 2012, 109, 20006-20011.
30. Plattner, N.; Noé, F. Protein conformational plasticity and complex ligand-binding kinetics explored by atomistic simulations and Markov models. Nat. Commun. 2015, 6, doi:10.1038/ncomms8653.
31. Kappel, K.; Wereszczynski, J.; Clubb, R.T.; McCammon, J.A. The binding mechanism, multiple binding modes, and allosteric regulation of Staphylococcus aureus Sortase A probed by molecular dynamics simulations. Protein Sci. Publ. Protein Soc. 2012, 21, 1858-1871.
32. McClendon, C.L.; Kornev, A.P.; Gilson, M.K.; Taylor, S.S. Dynamic architecture of a protein kinase. Proc. Natl. Acad. Sci. USA 2014, 111, E4623-E4631.
33. Tan, Y.S.; Spring, D.R.; Abell, C.; Verma, C.S. The application of ligand-mapping molecular dynamics simulations to the rational design of peptidic modulators of protein-protein interactions. J. Chem. Theory Comput. 2015, 11, 3199-3210.
34. Wilson, C.G.; Arkin, M.R. Probing structural adaptivity at PPI interfaces with small molecules. Drug Discov. Today Technol. 2013, 10, e501-e508.
35. Silvian, L.; Friedman, J.; Strauch, K.; Cachero, T.; Day, E.; Qian, F.; Cunningham, B.; Fung, A.; Sun, L.; Su, L.; et al. Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture Mechanism. ACS Chem. Biol. 2011, 6, 636-647.
36. Cooper, A.; Dryden, D.T. Allostery without conformational change. A plausible model. Eur. Biophys. J. 1984, 11, 103-109.
37. McLeish, T.C.B.; Rodgers, T.L.; Wilson, M.R. Allostery without conformation change: Modelling protein dynamics at multiple scales. Phys. Biol. 2013, 10, 056004.
38. Brooks, B.; Karplus, M. Harmonic Dynamics of Proteins: Normal Modes and Fluctuations in Bovine Pancreatic Trypsin Inhibitor. Proc. Natl. Acad. Sci. USA 1983, 80, 6571-6575.
39. Rodgers, T.L.; Townsend, P.D.; Burnell, D.; Jones, M.L.; Richards, S.A.; McLeish, T.C.B.; Pohl, E.; Wilson, M.R.; Cann, M.J. Modulation of Global Low-Frequency Motions Underlies Allosteric Regulation: Demonstration in CRP/FNR Family Transcription Factors. PLoS Biol. 2013, 11, e1001651.
40. Townsend, P.D.; Rodgers, T.L.; Glover, L.C.; Korhonen, H.J.; Richards, S.A.; Colwell, L.J.; Pohl, E.; Wilson, M.R.; Hodgson, D.R.W.; McLeish, T.C.B.; et al. The Role of Protein-Ligand Contacts in Allosteric Regulation of the Escherichia coli Catabolite Activator Protein. J. Biol. Chem. 2015, doi:10.1074/jbc.M115.669267.
41. Frederick, K.K.; Marlow, M.S.; Valentine, K.G.; Wand, A.J. Conformational entropy in molecular recognition by proteins. Nature 2007, 448, 325-329.
42. Jarymowycz, V.A.; Stone, M.J. Remote changes in the dynamics of the phosphotyrosine-binding domain of insulin receptor substrate-1 induced by phosphopeptide binding. Biochemistry (Mosc.) 2008, 47, 13371-13382.
43. Shimaoka, M.; Xiao, T.; Liu, J.-H.; Yang, Y.; Dong, Y.; Jun, C.-D.; McCormack, A.; Zhang, R.; Joachimiak, A.; Takagi, J.; et al. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 2003, 112, 99-111.
44. Shimaoka, M.; Lu, C.; Palframan, R.T.; von Andrian, U.H.; McCormack, A.; Takagi, J.; Springer, T.A. Reversibly locking a protein fold in an active conformation with a disulfide bond: Integrin αL I domains with high affinity and antagonist activity in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 6009-6014.
45. Watterson, S.H.; Xiao, Z.; Dodd, D.S.; Tortolani, D.R.; Vaccaro, W.; Potin, D.; Launay, M.; Stetsko, D.K.; Skala, S.; Davis, P.M.; et al. Small Molecule Antagonist of Leukocyte Function Associated Antigen-1 (LFA-1): Structure-Activity Relationships Leading to the Identification of 6-((5S, 9R)-9-(4-Cyanophenyl)-3-(3, 5-dichlorophenyl)-1-methyl-2, 4-dioxo-1, 3, 7-triazaspiro[4.4] nonan-7-yl)nicotinic Acid (BMS-688521). J. Med. Chem. 2010, 53, 3814-3830.
46. McMillan, K.; Adler, M.; Auld, D.S.; Baldwin, J.J.; Blasko, E.; Browne, L.J.; Chelsky, D.; Davey, D.; Dolle, R.E.; Eagen, K.A.; et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. USA 2000, 97, 1506-1511.
47. Gorczynski, M.J.; Grembecka, J.; Zhou, Y.; Kong, Y.; Roudaia, L.; Douvas, M.G.; Newman, M.; Bielnicka, I.; Baber, G.; Corpora, T.; et al. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem. Biol. 2007, 14, 1186-1197.
48. Gabizon, R.; Friedler, A. Allosteric modulation of protein oligomerization: An emerging approach to drug design. Front. Chem. 2014, 2, doi:10.3389/fchem.2014.00009.
49. Mitra, A.; Sept, D. Taxol Allosterically Alters the Dynamics of the Tubulin Dimer and Increases the Flexibility of Microtubules. Biophys. J. 2008, 95, 3252-3258.
50. Prota, A.E.; Bargsten, K.; Zurwerra, D.; Field, J.J.; Díaz, J.F.; Altmann, K.-H.; Steinmetz, M.O. Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents. Science 2013, 339, 587-590.
51. Silvian, L.; Enyedy, I.; Kumaravel, G. Inhibitors of protein-protein interactions: New methodologies to tackle this challenge. Drug Discov. Today Technol. 2013, 10, e509-e515.
52. Arkin, M.R.; Glicksman, M.A.; Fu, H.; Havel, J.J.; Du, Y. Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats. In Assay Guidance Manual; Sittampalam, G.S., Coussens, N.P., Nelson, H., Arkin, M., Auld, D., Austin, C., Bejcek, B., Glicksman, M., Inglese, J., Iversen, P.W., et al., Eds.; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, USA, 2004.
53. Smith, M.C.; Gestwicki, J.E. Features of protein-protein interactions that translate into potent inhibitors: Topology, surface area and affinity. Expert Rev. Mol. Med. 2012, 14, doi:10.1017/erm.2012.10.
54. Day, E.S.; Cote, S.M.; Whitty, A. Binding Efficiency of Protein-Protein Complexes. Biochemistry (Mosc.) 2012, 51, 9124-9136.
55. Kew, J.N.C. Positive and negative allosteric modulation of metabotropic glutamate receptors: Emerging therapeutic potential. Pharmacol. Ther. 2004, 104, 233-244.
56. Heitner, T.R.; Hansen, N.J.V. Streamlining hit discovery and optimization with a yoctoliter scale DNA reactor. Expert Opin. Drug Discov. 2009, 4, 1201-1213.
57. Blakskjaer, P.; Heitner, T.; Hansen, N.J.V. Fidelity by design: Yoctoreactor and binder trap enrichment for small-molecule DNA-encoded libraries and drug discovery. Curr. Opin. Chem. Biol. 2015, 26, 62-71.
58. Wielens, J.; Headey, S.J.; Rhodes, D.I.; Mulder, R.J.; Dolezal, O.; Deadman, J.J.; Newman, J.; Chalmers, D.K.; Parker, M.W.; Peat, T.S.; et al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J. Biomol. Screen. 2013, 18, 147-159.
59. Drinkwater, N.; Cossins, B.P.; Keeble, A.H.; Wright, M.; Cain, K.; Hailu, H.; Oxbrow, A.; Delgado, J.; Shuttleworth, L.K.; Kao, M.W.-P.; et al. Human immunoglobulin E flexes between acutely bent and extended conformations. Nat. Struct. Mol. Biol. 2014, 21, 397-404.
60. Dror, R.; Arlow, D.; Borhani, D.; Jensen, M.; Piana, S.; Shaw, D. Identification of two distinct inactive conformations of the β2-adrenergic receptor reconciles structural and biochemical observations. Proc. Natl. Acad. Sci. USA 2009, 106, 4689-4694.
61. Bowman, G.R.; Geissler, P.L. Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites. Proc. Natl. Acad. Sci. USA 2012, 109, 11681-11686.
62. Sugita, Y.; Okamoto, Y. Replica-exchange molecular dynamics method for protein folding. Chem. Phys. Lett. 1999, 314, 141-151.
63. Branduardi, D.; Gervasio, F.; Parrinello, M. From A to B in free energy space. J. Chem. Phys. 2007, 126, 054103.
64. Lawson, A.D.G. Antibody-enabled small-molecule drug discovery. Nat. Rev. Drug Discov. 2012, 11, 519-525.
65. Cossins, B.P.; Lawson, A.D.G. DEER-Refinement of X-Ray Crystal Structures to Guide Medicinal Chemistry. J. Drug Des. Res. 2015, 2, 1013.
66. Dror, R.O.; Green, H.F.; Valant, C.; Borhani, D.W.; Valcourt, J.R.; Pan, A.C.; Arlow, D.H.; Canals, M.; Lane, J.R.; Rahmani, R.; et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 2013, 14, 295-259.
67. Shaw, D.E.; Maragakis, P.; Lindorff-Larsen, K.; Piana, S.; Dror, R.O.; Eastwood, M.P.; Bank, J.A.; Jumper, J.M.; Salmon, J.K.; Shan, Y.; et al. Atomic-Level Characterization of the Structural Dynamics of Proteins. Science 2010, 330, 341-346.
68. Kohlhoff, K.J.; Shukla, D.; Lawrenz, M.; Bowman, G.R.; Konerding, D.E.; Belov, D.; Altman, R.B.; Pande, V.S. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways. Nat. Chem. 2014, 6, 15-21.
69. Lovera, S.; Sutto, L.; Boubeva, R.; Scapozza, L.; Dölker, N.; Gervasio, F.L. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J. Am. Chem. Soc. 2012, 134, 2496-2499.
70. Camilloni, C.; Robustelli, P.; Simone, A.D.; Cavalli, A.; Vendruscolo, M. Characterization of the Conformational Equilibrium between the Two Major Substates of RNase A Using NMR Chemical Shifts. J. Am. Chem. Soc. 2012, 134, 3968-3971.
71. McClendon, C.L.; Friedland, G.; Mobley, D.L.; Amirkhani, H.; Jacobson, M.P. Quantifying Correlations between Allosteric Sites in Thermodynamic Ensembles. J. Chem. Theory Comput. 2009, 5, 2486-2502.
72. Larion, M.; Hansen, A.L.; Zhang, F.; Bruschweiler-Li, L.; Tugarinov, V.; Miller, B.G.; Brüschweiler, R. Kinetic Cooperativity in Human Pancreatic Glucokinase Originates from Millisecond Dynamics of the Small Domain. Angew. Chem. Int. Ed. 2015, 54, 8129-8132.
73. Su, J.G.; Qi, L.S.; Li, C.H.; Zhu, Y.Y.; Du, H.J.; Hou, Y.X.; Hao, R.; Wang, J.H. Prediction of allosteric sites on protein surfaces with an elastic-network-model-based thermodynamic method. Phys. Rev. E 2014, 90, 022719.
74. Guvench, O.; MacKerell, A.D. Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation. PLoS Comput. Biol. 2009, 5, e1000435.
75. Erlanson, D.A.; Wells, J.A.; Braisted, A.C. Tethering: Fragment-Based Drug Discovery. Annu. Rev. Biophys. Biomol. Struct. 2004, 33, 199-223.
76. Yildiz, M.; Ghosh, S.; Bell, J.A.; Sherman, W.; Hardy, J.A. Allosteric Inhibition of the NS2B-NS3 Protease from Dengue Virus. ACS Chem. Biol. 2013, 8, 2744-2752.
77. Bowman, G.R.; Bolin, E.R.; Hart, K.M.; Maguire, B.C.; Marqusee, S. Discovery of multiple hidden allosteric sites by combining Markov state models and experiments. Proc. Natl. Acad. Sci. USA 2015, 112, 2734-2739.
78. Perica, T.; Kondo, Y.; Tiwari, S.P.; McLaughlin, S.H.; Kemplen, K.R.; Zhang, X.; Steward, A.; Reuter, N.; Clarke, J.; Teichmann, S.A. Evolution of oligomeric state through allosteric pathways that mimic ligand binding. Science 2014, 346, 1254346.